Definitive Contract 75N93019C00021
Award Date
8/26/19
Potential Completion Date
8/25/20
Potential Value
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Zymeron Corporation
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Research Triangle Park, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
15
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
STTR Phase I
Primary Consortia Member
Not listed
Similar Awards
The Zymeron Corporation was awarded a $299,998 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract is for the research and development of a rapid point-of-care diagnostic test for histoplasmosis. This award falls under the larger SBIR solicitation issued by NIH and CDC seeking proposals in areas including cancer immunotherapy manufacturing, opioid withdrawal...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000.00 firm-fixed-price definitive contract to Zymeron Corporation, a minority-owned small business, to provide rapid point-of-care tests to quantify hepatitis C virus. The contract has an estimated completion date of August 30, 2022 and was awarded on August 31, 2021. Zymeron is a research-based biotechnology company that develops innovative technologies...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a Small Business Innovation Research (SBIR) Phase I contract to Zymeron Corporation, a minority-owned biotechnology company, with a ceiling value of $300,000.00. The objective of this firm-fixed-price contract is for Zymeron to design and synthesize compounds that bind to Nef, an HIV accessory protein, as part of the agency's Small Molecule Degraders of Intracellular HIV Proteins as Novel Anti-HIV Therapeutics major...
This is a $299,988 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Zymeron Corporation, a minority-owned small business. The contract is for the development of novel, low-cost, real-time point-of-care (POC) assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring. This contract was awarded under the Small Business Innovation...
Zymeron Corporation has been awarded a $300,000 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under this contract, Zymeron will develop a novel nanoparticle delivery system to elicit a potent and long-lasting antibody response and broad neutralizing activity against HIV, as requested under the Centers for Disease Control and Prevention and NIH solicitation seeking...
This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
This contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Zymeron Corporation, a Minority Owned small business, under the Small Business Innovation Research (SBIR) Program. The objective is to develop a new chemical entity drug for proteolytic degradation of HIV Gag proteins. The contract is a Firm Fixed Price Definitive Contract with a potential value of $299,794.00 and a...
Zymeron Corporation has been awarded a $300,000 firm fixed price definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to deliver an orodispersible film formulation of a second line drug for pediatric tuberculosis treatment. The contract is set aside for total small businesses and will be completed by August 31, 2022. Performance will take place in Durham, North Carolina. This award supports the National Institute of Allergy and...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000 firm fixed price definitive contract to Zymeron Corporation under SBIR PHS 2020-1 Topic 084. This Small Business Innovation Research Phase I contract supports research and development of antiviral drugs to cure chronic hepatitis B virus infection. The solicitation sought proposals for Phase I and Phase II SBIR contracts to advance the missions of...
<p>The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000 Firm Fixed Price Definitive Contract to Zymeron Corporation to develop Point-of-Care Diagnostics for Antimicrobial Resistant Enteric Bacterial and Parasitic Pathogens. The work will be performed in Research Triangle Park, North Carolina over a one year period ending June 30, 2023. No subcontractors were identified.</p>